BIOMAT Database Logo BIOMAT Database Logo

Immunological alterations in patients with primary tumors in central nervous system. 1999

M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Department of Microbiology and Immunology, State University of São Paulo (UNESP), Botucatu, Brazil. Peracoli@botunet.com.br

Natural killer (NK) cells play an important role in immune surveillance against tumors. The present work aimed to study the cytotoxic activity of NK cells and T cell subsets in peripheral blood of 13 patients with primary tumors in central nervous system (CNS). As controls 29 healthy subjects with the age range equivalent to the patients were studied. The methods employed were: a) determination of cytotoxic activity of NK cells towards K562 target cells, evaluated by single cell-assay; b) enumeration of CD3+ lymphocytes and their CD4+ and CD8+ subsets defined by monoclonal antibodies; c) the identification of tumors were done by histologic and immunochemistry studies. The results indicated that adults and children with tumor in CNS display reduced percentage of total T cells, helper/inducer subset and low helper/suppressor ratio. The cytotoxic activity of NK cells was decreased in patients with CNS tumors due mainly to a decrease in the proportion of target-binding lymphocytes. These results suggest that cytotoxic activity of NK cells may be affected by the immunoregulatory disturbances observed in patients with primary tumors in CNS.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Immunological studies in patients with central nervous system tumors.
January 1987, Journal of neuro-oncology,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Rare primary central nervous system tumors.
July 2014, Rare tumors,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Primary Central Nervous System Tumors in Children.
November 1999, Current treatment options in neurology,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Primary Central Nervous System Tumors in Adults.
November 1999, Current treatment options in neurology,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Histological features in pediatric central nervous system tumors with FGFR alterations.
January 2020, Folia neuropathologica,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Epilepsy in patients with central nervous system tumors.
December 1996, Current opinion in neurology,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Primary central nervous system germ cell tumors.
December 2003, Current treatment options in oncology,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
Epidemiology of primary central nervous system tumors.
January 2012, Handbook of clinical neurology,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
[Primary tumors of the central nervous system].
September 1981, Revue medicale de la Suisse romande,
M T Peraçoli, and T C Montelli, and A M Soares, and M R Parise-Fortes, and S A Alquati, and A Ueda, and M R Montenegro, and A Alves, and R C Gabarra, and T P Faleiros, and M A Zanini
SETD2 mutations in primary central nervous system tumors.
November 2018, Acta neuropathologica communications,
Copied contents to your clipboard!